Qiagen (QGEN) said Tuesday the German Federal Patent Court reaffirmed the validity of a patent protecting its QuantiFeron technology.
The court's decision upholds Qiagen's intellectual property rights involving the German part of a European patent, which protects its technology in detecting latent tuberculosis, the company said late Tuesday.
"Patents covering these innovations have been issued to Qiagen in several other countries, and form part of a group of more than 120 patents currently issued for QuantiFERON," the company added.